Last update 15 Dec 2024
Sudubrilimab
Last update 15 Dec 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Recombinant anti-PD-L1 human monoclonal antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.), HS-636 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 453187173L
Source: *****
Sequence Code 453187174H
Source: *****
Related
3
Clinical Trials associated with Sudubrilimab重组抗PD-L1全人源单克隆抗体注射液（HS636）治疗复发或难治性原发纵膈大B细胞淋巴瘤多中心、开放、单臂Ⅱ期临床试验
[Translation] A multicenter, open, single-arm phase II clinical trial of recombinant anti-PD-L1 fully human monoclonal antibody injection (HS636) for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma
重组抗PD-L1全人源单克隆抗体注射液（HS636）单药及联合白蛋白结合型紫杉醇治疗晚期三阴性乳腺癌（TNBC）患者的Ib/II期临床试验
[Translation] Phase Ib/II clinical trial of recombinant anti-PD-L1 fully human monoclonal antibody injection (HS636) alone and in combination with albumin-bound paclitaxel in the treatment of patients with advanced triple-negative breast cancer (TNBC)
重组抗PD-L1全人源单克隆抗体注射液HS636单药在晚期恶性肿瘤受试者中的安全性耐受性的开放性剂量递增I期临床试验
[Translation] An open-label, dose-escalation phase I clinical trial of the safety and tolerability of HS636, a recombinant anti-PD-L1 fully human monoclonal antibody injection, in subjects with advanced malignant tumors
100 Clinical Results associated with Sudubrilimab
Login to view more data
100 Translational Medicine associated with Sudubrilimab
Login to view more data
100 Patents (Medical) associated with Sudubrilimab
Login to view more data
100 Deals associated with Sudubrilimab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Phase 2 | CN | 30 Jan 2022 | |
| Solid tumor | Phase 2 | CN | 30 Jan 2022 | |
| Primary mediastinal large B-cell lymphoma recurrent | Phase 2 | CN | 27 Oct 2021 | |
| Primary mediastinal large B-cell lymphoma refractory | Phase 2 | CN | 27 Oct 2021 | |
| Advanced Triple-Negative Breast Carcinoma | Phase 2 | CN | 18 Oct 2021 | |
| Advanced cancer | Phase 1 | CN | 14 Mar 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free